A vasoactive intestinal peptide antagonist inhibits non-small cell lung cancer growth.

The most prevalent lung cancer, non-small cell lung cancer (NSCLC) has receptors for vasoactive intestinal peptide (VIP). Here the effects of a VIP antagonist (VIP-hyb) on NSCLC growth were investigated. In vivo, when VIPhyb (10 micrograms, s.c.) was daily injected into nude mice, xenograft formatio...

ver descrição completa

Detalhes bibliográficos

Publicado no:	Proc Natl Acad Sci U S A
Principais autores:	Moody, T W, Zia, F, Draoui, M, Brenneman, D E, Fridkin, M, Davidson, A, Gozes, I
Formato:	Artigo
Idioma:	Inglês
Publicado em:	National Academy of Sciences 1993
Assuntos:	Research Article
Acesso em linha:	https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC46507/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/8389448/ https://ncbi.nlm.nih.govhttps://doi.org/10.1073/pnas.90.10.4345
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!